IL1B and chronic kidney disease: Importantly, blocking the IL-1β pathway reduces cardiovascular events in CKD patients, as demonstrated by the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) secondary prevention trial, which assessed the effect of IL-1β inhibition by canakinumab on the risk of major cardiovascular events in 1875 CKD patients [69].